Our goal is to develop life-saving medicines for patients with rare respiratory diseases
At Altavant, we are driven by several objectives:
- Develop rodatristat ethyl*, our lead TPH inhibitor candidate for the treatment of patients with pulmonary arterial hypertension (PAH). Rodatristat ethyl is currently in Phase 2 clinical development for PAH and has the potential to address the underlying cause, and not merely symptoms, of PAH. It also holds promise to treat several other rare respiratory diseases, including idiopathic pulmonary fibrosis (IPF).
- Develop ALTA-2530, an inhaled formulation of an interleukin-1 receptor antagonist (IL-1Ra), for the treatment of bronchiolitis obliterans syndrome (BOS), the leading cause of morbidity and mortality in post-lung transplant patients, and chemical lung injury.
- Design and evaluate new treatments for other respiratory diseases such as PAH, BOS, IPF and sarcoidosis that are progressive and often fatal – yet where most current therapies do not halt or reverse the course of the disease.
- Explore additional opportunities to expand our pipeline to address other rare respiratory diseases with high unmet medical needs.
To pursue a patient-centric, transparent development approach
- Altavant is committed to understanding the extent of the medical need and the daily challenges patients with rare respiratory diseases face. We are pursuing innovative ways to include input from patient advocacy groups and the patient community in our research and development efforts. Our clinical trials will be designed to take the needs of patients into consideration and we will be as transparent as possible within the confines of the clinical trial process.
To build a corporate culture that celebrates new ideas and persistence
- The Altavant team is passionate about building a culture that celebrates new ideas and persistence, with a deep commitment to pursuing scientific innovation and novel approaches to drug development.